Dougan Brady W

Director Brady W Dougan sold entire 2.24M share stake over 3 days for $3.7M; complete exit from unprofitable biotech down 76.9% from 52-week high

Dougan Brady W, a Director at Humacyte, Inc., executed 3 separate sales totaling 2,241,045 shares for $3,733,191.10 across August 18–20, 2025, completely liquidating his holdings at a blended average price of $1.67. This represents a complete exit from the company, liquidating a position at prices substantially depressed: the stock is now $1.63 current price, down 76.9% from its 52-week high of $7.05 and down 29.1% over the prior 30 days. The company's fundamentals remain stressed—latest quarter revenue was only $301,000.00 and the company is unprofitable with net income of $-37,658,000.00 over the most recent full fiscal year. At the same ticker, Dougan's prior 5 trades show a 4-of-5 pattern of well-timed executions at the 90-day mark, with prior sells consistently followed by declines; however, all post-transaction measurements must await future price action. The complete liquidation of a director's entire stake warrants investor attention as a fundamental departure from partial reductions, particularly given the company's severely depressed valuation and continued unprofitability.

Director Dougan Brady W bought 1,797 shares of HUMA at $4.44 on 2024-11-19, adding 0.7% to holdings in a stock down 53.7% from 52-week high.

Dougan Brady W purchased 1,797 shares at $4.44 on 2024-11-19, a modest 0.7% addition to his 242.1K share base. The transaction occurred as HUMA has fallen 53.7% from its 52-week high of $9.46, with the stock declining 20.1% over the preceding 30 days and 37.7% over 90 days. Across his three prior open-market buys at other tickers, Brady W's average 30-day and 90-day returns were -16.2% and -11.3% respectively, with a 0.00% 90-day win rate. His five prior HUMA trades have all been sells; the two most recent (2024-11-20 and 2024-11-19) lack measurable outcomes, while earlier sales on 2024-11-18, 2024-09-10, and 2024-09-09 have not yet demonstrated well-timed exits at the 90-day mark. The company reported $241.0K revenue in its latest quarter against a net loss of $39.2M, with unprofitable results for the full fiscal year, reflecting a capital-intensive early-stage biotech model.

Director Brady W Dougan sold 1,500,000 shares (1.50M) for $6.6M across 3 days; stock down -53.4% from 52-week high, company unprofitable

Director Dougan executed three separate sales totaling 1,500,000 shares for $6,606,799.34 between November 18–20, 2024, reducing his holdings by -46.4% from 3,230,884 to 1,730,884 shares. The sales occurred at a blended average price of $4.40, while the stock now trades at $4.41 (current price). Against a 52-week high of $9.46, the stock is -53.4% off its peak and -31.1% over the prior 90 days, signaling sustained price deterioration in the window surrounding this filing. Humacyte remains unprofitable with full-year negative net income and latest-quarter revenue of only $241,000.00, placing the $555.0M market cap under pressure. Douhan's cross-ticker selling history shows a 90.91% well-timed rate on prior sells (average 90-day return -22.5%), suggesting his sell patterns have historically preceded declines, though his prior 5 trades at HUMA lack meaningful measurable outcomes, preventing any ticker-specific timing assessment.

Director Brady Dougan sells 446,378 shares (12.1% of holdings) at $5.30 avg as stock falls 14% in 30 days and company remains unprofitable

Brady Dougan, a Director at Humacyte, executed 2 separate sales totaling 446,378 shares for $2,364,520.70 on September 9–10, reducing his holdings from 3.68M to 3.23M shares. The sales occurred at a blended average price of $5.30, which is now 7.3% above the current price of $5.69, and represent a 12.1% reduction in his stake during a period when HUMA has declined 14.0% over 30 days and 21.0% over 90 days from his transaction date. The company's fundamentals remain challenged—it reported revenue of $241,000.00 in its latest quarter and a net loss of $56,663,000.00, with the company remaining unprofitable over the most recent full fiscal year. Dougan's prior sales at this ticker show a 90-day well-timed rate of 100% (his June 12 sale fell 28.1% in 90 days), and his cross-ticker sell track record demonstrates a 71.43% well-timed rate, suggesting a pattern of selling before price deterioration.

Director Dougan Brady W bought 1,222 shares of HUMA at $6.54 on 2024-08-29; stock now $5.54, -41.4% from 52-week high.

Director Dougan Brady W purchased 1,222 shares at $6.54 on 2024-08-29, a modest addition to his 240,832-share position. The purchase occurred as HUMA was trading near the low end of its 52-week range, down 41.4% from its high and -32.8% over the prior 30 days. However, this buy must be weighed against both his contemporaneous sell activity and his mixed track record: on the same day (2024-08-29) he sold shares, and his prior two open-market buys across all tickers averaged -16.9% returns over 30 days and -11.3% over 90 days with a 0% win rate. At the same ticker, his prior five trades were all sells (three on consecutive dates 2024-08-27 through 2024-08-29), suggesting recent net selling pressure from this director. Additionally, the company is unprofitable with net income of $-56.7M against quarterly revenue of $241.0K, indicating fundamental challenges rather than temporary valuation distortion.

Director Dougan Brady W sold 881,878 shares ($5.7M) across 3 days at $6.71–$6.35; stock now $6.15, down 35.0% from 52-week high.

Director Dougan Brady W executed 3 separate sales totaling 881,878 shares for $5,724,139.46 between August 27–29, 2024, at prices ranging from $6.71 to $6.35 (blended average $6.49), reducing his holdings by -19.3% from 4,559,140 to 3,677,262 shares. The stock has since fallen to $6.15, representing a -35.0% decline from its 52-week high of $9.46 and a -25.0% drop over the prior 30 days, placing the sale prices near the top of recent trading activity. The company remains unprofitable with net income of $-56,663,000.00 for its most recent full fiscal year and quarterly revenue of just $241,000.00, creating a disconnect between valuation ($734.0M market cap) and operational performance that investors should monitor closely.